Avita Medical Awarded US Government Contract valued at up to $53. 9 m USD

Link here. 30 September 2015.


BARDA contract commits initial USD16.9m to support Avita’s FDA approval trial for treatment of thermal burn injuries and procure 5000-plus ReCell® devices.

Contract also establishes a strategic, Avita-managed stockpile for ReCell® devices to supply nationally.

A further potential to receive USD37M in contract options to support additional clinical trials and provide surge capacity for up to 20,000 ReCell® devices.

Contract aim is to address BARDA’s stated requirement for autograft-sparing products intended to bolster the government’s ability to respond to potential sudden surges in burn care, and improve the standard of US burn care.